Notably, recombinant non-pathogenic polio-rhinovirus chimera (PVSRIPO), which binds the poliovirus receptor CD155 on cancer cells, was evaluated in 61 GBM patients via intra-tumoral injection and was effective in 21% patients who survived past 36 months (95). The gene discussed is PVR; the disease is cancer.